Finance entity
earnings is the sole category represented across all 1 tracked stories. Fulgent Genetics is most often covered alongside ANI Pharmaceuticals, which appears in 1 of these 1 story. Source depth averages 4 original sources per story, versus 2.6 across the same-window beat baseline.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
earnings is the sole category represented across all 1 tracked stories. Fulgent Genetics is most often covered alongside ANI Pharmaceuticals, which appears in 1 of these 1 story. Source depth averages 4 original sources per story, versus 2.6 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6. We currently track 1 Finance story that mention Fulgent Genetics, all published on February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 120 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Fulgent Genetics. Shared-story counts are live from our verified record — not editorial picks.
ANI Pharmaceuticals and Amneal Pharmaceuticals are preparing to report Q4 2025 results, with investors focusing on rare disease expansion and biosimilar adoption. The broader earnings window also features updates from Fulgent Genetics and Alpha Metallurgical, highlighting a diverse landscape of diagnostic shifts and commodity pricing.
Fulgent Genetics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
